Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma

Authors: Weizheng Zhou, Hui Yue, Chunguang Li, Hezhong Chen, Yang Yuan

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Dysregulation of protein arginine methyltransferase 1 (PRMT1) has been reported in several cancer types. However, its expression pattern and biological functions in esophageal squamous cell carcinoma (ESCC) remained unknown. Here, we have found that the expression of PRMT1 was up-regulated in ESCC samples. In the biological function studies, forced expression of PRMT1 promoted the growth and migration of ESCC cells. However, knocking down the expression of PRMT1 inhibited the growth, migration, and metastasis of ESCC cells. Moreover, PRMT1 activated Hedgehog signaling and up-regulated the expression of target genes downstream of Hedgehog signaling. Taken together, our study revealed the oncogenic roles of PRMT1 in the progression of ESCC, and PRMT1 might be a promising therapeutic target for the treatment of ESCC.
Literature
1.
Baldwin RM, Morettin A, Cote J. Role of PRMTs in cancer: could minor isoforms be leaving a mark? World Journal of Biological Chemistry. 2014;5:115–29.PubMedPubMedCentral
2.
Kleinschmidt MA, Streubel G, Samans B, Krause M, Bauer UM. The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation. Nucleic Acids Res. 2008;36:3202–13.CrossRefPubMedPubMedCentral
3.
Yeh HY, Klesius PH. Molecular characterization, phylogenetic analysis and expression patterns of five protein arginine methyltransferase genes of channel catfish, ictalurus punctatus (rafinesque). Fish Physiol Biochem. 2012;38:1083–98.CrossRefPubMed
4.
Nicholson TB, Chen T, Richard S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol Res. 2009;60:466–74.CrossRefPubMed
5.
Guendel I, Carpio L, Pedati C, et al. Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS One. 2010;5:e11379.CrossRefPubMedPubMedCentral
6.
Benhenda S, Ducroux A, Riviere L, et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol. 2013;87:4360–71.CrossRefPubMedPubMedCentral
7.
Davies CC, Chakraborty A, Diefenbacher ME, Skehel M, Behrens A. Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/AP-1 activation. EMBO J. 2013;32:1556–67.CrossRefPubMedPubMedCentral
8.
Chaib H, Prebet T, Vey N, Collette Y. Histone methyltransferases: a new class of therapeutic targets in cancer treatment? Med Sci (Paris). 2011;27:725–32.CrossRef
9.
Yoshimatsu M, Toyokawa G, Hayami S, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011;128:562–73.CrossRefPubMed
10.
Baldwin RM, Bejide M, Trinkle-Mulcahy L, Cote J. Identification of the prmt1v1 and prmt1v2 specific interactomes by quantitative mass spectrometry in breast cancer cells. Proteomics. 2015.
11.
Baldwin RM, Morettin A, Paris G, Goulet I, Cote J. Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle. 2012;11:4597–612.CrossRefPubMedPubMedCentral
12.
Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, et al. PRMT1 is a novel regulator of epithelial-mesenchymal-transition in non-small cell lung cancer. J Biol Chem. 2015;290:13479–89.CrossRefPubMedPubMedCentral
13.
Papadokostopoulou A, Mathioudaki K, Scorilas A, et al. Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res. 2009;29:1361–6.PubMed
14.
Goulet I, Gauvin G, Boisvenue S, Cote J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem. 2007;282:33009–21.CrossRefPubMed
15.
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.CrossRefPubMed
16.
Abidi A. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian Journal of Pharmacology. 2014;46:3–12.CrossRefPubMedPubMedCentral
17.
Ma X, Sheng T, Zhang Y, et al. Hedgehog signaling is activated in subsets of esophageal cancers. Int J Cancer. 2006;118:139–48.CrossRefPubMed
18.
Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs. 2013;73:613–23.CrossRefPubMed
19.
Saito T, Mitomi H, Yao T. Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma. Int J Clin Exp Pathol. 2012;8:2267–73.
20.
Yang L, Wang LS, Chen XL, et al. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. International Journal of Biochemistry and Molecular Biology. 2012;3:46–57.PubMedPubMedCentral
21.
Abdel-Rahman O. Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials. Tumour Biol. 2015;36:1367–74.CrossRefPubMed
22.
Ke Z, Caiping S, Qing Z, Xiaojing W. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Medical Oncology (Northwood, London, England). 2015;32:368.CrossRef
23.
Shin K, Lim A, Zhao C, et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell. 2014;26:521–33.CrossRefPubMedPubMedCentral
24.
25.
Gonnissen A, Isebaert S, Haustermans K. Targeting the hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015.
26.
Smoothened mutations underlie basal cell carcinoma resistance. Cancer Discov. 2015;5:OF9.
27.
Dillon MB, Bachovchin DA, Brown SJ, et al. Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization. ACS Chem Biol. 2012;7:1198–204.CrossRefPubMedPubMedCentral
28.
Zakrzewicz D, Zakrzewicz A, Wilker S, et al. Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts. Nephrol Dial Transplant. 2011;26:124–35.CrossRefPubMed
Metadata
Title
Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma
Authors
Weizheng Zhou
Hui Yue
Chunguang Li
Hezhong Chen
Yang Yuan
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4098-3

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer

Original Article

Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells

Review

Inhibitory effects of Arhgap6 on cervical carcinoma cells

Original Article

Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells

Original Article

G648C variant of DNA polymerase β sensitizes esophageal cancer to chemotherapy

Original Article

A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits